

EAHP Position Paper on Biosimilar Medicines

This paper sets out the position of the European Association of Hospital Pharmacists (EAHP) on important issues concerning biosimilars including the role of hospital pharmacists in the uptake of biosimilars in healthcare in terms of selection, procurement, logistics, information, education and collecting real life experience (e.g. in monitoring and pharmacovigilance).

A biological medicine is a medicine that contains one or more active substances made by or derived from a biological source i.e. living cells or organisms. The European Medicines Agency (EMA) defines a biosimilar medicine as “a medicine that is developed to be highly similar to another biological medicine already marketed in the EU (the so-called ‘reference medicine’)”.¹

Overall, EAHP has confidence in EMAs regulatory pathway for biological reference products and biosimilar medicines. EAHP, as for all other medicines, recommends informed patient involvement and shared decision making.

On matters concerning **naming of biosimilar medicines**, EAHP

- Supports that biosimilar medicines should hold the same INN as the reference product.

On matters concerning **extrapolation of indications**, EAHP

- Supports that where regulatory approval exists, extrapolation of indications is appropriate.

On matters concerning **interchangeability, switching and substitution of biosimilar medicines**, EAHP

- Supports that a reference product and its biosimilar(s) are interchangeable and therefore can be switched;
- Supports that a biosimilar product and other biosimilar(s) to the same reference product are interchangeable and therefore can be switched;
- Supports that decisions regarding switching and substitution should involve the relevant stakeholders (patients, prescribers, pharmacists and others);
- Acknowledges that such decisions may be made at the national level, involving the relevant stakeholders (patients, prescribers, pharmacists and others);
- Supports that under certain conditions substitution at hospital pharmacy level can occur.

On matters of **information about biosimilar medicines**, EAHP

- Calls upon competent authorities to take lead responsibility for the dissemination of unbiased information about biosimilar medicines. The expertise of hospital pharmacists should be consulted in the development of such information.

On matters relating to **the role of the hospital pharmacist**, EAHP

- Advocates for the use of the hospital pharmacist's knowledge in promoting the appropriate selection, procurement, logistics and use of biosimilar medicines, and in providing education about them to both patients and other health care professionals;
- Encourages the involvement of hospital pharmacists in pharmacovigilance;
- Calls for the utilisation of the expertise of hospital pharmacists by the relevant fora dealing with biosimilar medicines.

¹ European Medicines Agency and the European Commission (2017), 2017. Biosimilars in the EU –Information guide for healthcare professionals. Available at: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (last visited on 10 June 2023).

Naming of Biosimilar Medicines

Policy debate in respect of how biosimilar medicines should be named has been conducted at international² and national³ levels. Both the World Health Organisation (WHO) and the American Food and Drug Administration (FDA) advocate for the use of the same nonproprietary name to which a randomly generated four-letter code should be affixed at the end.⁴ Others argue that giving biosimilar medicines the same INN designation could make it harder to track adverse reactions and/or that random generated suffixes will make product recognition by prescribers, healthcare professionals and patients difficult. They suggest that this could potentially compromise patient safety. By contrast in Japan regulations have been instituted that require the biosimilar medicine to carry the non-proprietary name of the reference product, a mention that it is a “biosimilar” and a number indicating the order in which the biosimilar has been approved.⁵

Reflecting on these arguments, EAHP takes the position that biosimilar medicines should hold the same INN as the reference product. This avoids confusion over, or undermining of, well-formed regulatory oversight mechanisms for the safety of biosimilar medicines. Moreover, a suffix will make the naming system more confusing for prescribers, other healthcare professionals and patients.

Extrapolation of indications

Extrapolation of indications is defined as the regulatory and scientific process of granting a clinical indication to a medicine without relevant clinical efficacy and safety data. In such cases, clinical data are typically generated in one indication and, taking into account the overall information gained from the comparability exercise, may then be extrapolated to the other indications.⁶

EAHP supports EMA's use of scientific and regulatory principles when assessing whether extrapolation of indications is appropriate.

Interchangeability, switching and substitution of biosimilar medicines

Interchangeability: the possibility of exchanging one medicine for another medicine that is expected to have the same clinical effect. This could mean replacing a reference product with a biosimilar (or vice versa) or replacing one biosimilar with another.⁷

The regulatory process of EMA ensures that an approved biosimilar is highly similar to its reference product in terms of quality, safety and efficacy including immunogenicity. EMA and the Heads of Medicines Agencies (HMA) released a joint statement on 19 September 2022 on the scientific rationale of considering biosimilars, approved in the EU, as interchangeable with their reference products.⁸

Furthermore, since biosimilars have been shown to be highly similar to the same reference product, it is highly unlikely that there would be any problems concerning interchangeability between biosimilars. So far

² World Health Organization. Inn and biologicals. Available at: <https://www.who.int/teams/health-product-and-policy-standards/inn/inn-bio> (last visited on 10 June 2023).

³ Food and Drug Administration, 2017. Nonproprietary naming of biological products – guidance for industry. Available at: <https://www.fda.gov/files/drugs/published/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf> (last visited on 10 June 2023).

⁴ Final WHO biosimilar naming proposal resembles FDA approach. 2016. Available at: <https://www.idsupra.com/legalnews/final-who-biosimilar-naming-proposal-43314/> (last visited on 10 June 2023).

⁵ T. Arato. Recent regulations of biosimilars in Japan. 47th annual meeting, 2011 Jun 19–23. Chicago, USA: Pharmaceuticals and Medical Devices Agency, 2011.

⁶ M. Weise, P. Kurki, E. Wolff-Holz, et al. Biosimilars: the science of extrapolation. *Blood* 2014;124:3191–6.

⁷ European Medicines Agency and the European Commission (2017), 2017. Biosimilars in the EU –Information guide for healthcare professionals. Available at: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (last visited on 10 June 2023).

⁸ European Medicines Agency and Heads of Medicines Agencies, 19 September 2022, Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. Available at: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf (last visited on 10 June 2023).

no studies have addressed this question, but the risk management plans of all biosimilars include an obligation to search for switch-related adverse events.⁹

Switching: the decision by the treating physician to exchange one medicine for another medicine with the same therapeutic intent.¹⁰

Substitution: the practice of dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber.¹¹

EAHP supports the view that a reference product and its biosimilar(s) are interchangeable and therefore can be switched. EAHP holds the same view for biosimilars to the same reference product. Nevertheless, due to patient specific issues there are instances where it is not appropriate to make a switch. It should therefore be ensured that the considerations of the prescriber, the pharmacist and the patient whether to choose the reference product or its biosimilar are taken into account.

Provided that the above safeguards are in place, EAHP supports substitution at hospital pharmacy level. In both instances, it is acknowledged by EAHP that decisions regarding switching and substitution may be taken on either national or local level.

Information on biosimilar medicines

The provision of unbiased information to the relevant stakeholders in national health systems is key to enabling sound discussions resulting in appropriate decisions on the use of biosimilar medicines. Such information should make it possible to understand the relevant terms and concepts, i.e. "biosimilar", "reference product", "comparability exercise", "extrapolation", "interchangeability", "switching" and "substitution".¹²

Competent authorities and other unbiased information providers such as national medicines information centres should be responsible for the dissemination of information about biosimilar medicines to stakeholders in the national health systems (payers, health professionals and patients).

EAHP advocates that the providers should refer to and consult the expertise of the hospital pharmacy profession in the development and dissemination of such information including education of patients and health care personnel.

The role of the hospital pharmacist

Hospital pharmacists are stewards of the appropriate selection, procurement, logistics, and use of medicines and are key players in pharmacovigilance. They are capable of, and uniquely positioned to promote the appropriate utilisation of biosimilar medicines.

Hospital pharmacists provide a 'hub of information' in terms of the uptake, best use and evidence base (i.e. monitoring of outcomes, real world use and reporting of adverse events). Their role is therefore particularly relevant with regard to switching and providing the evidence on patient safety and treatment quality. Their expert knowledge also puts hospital pharmacists in a position to provide advice on the quality, safety and efficacy of biosimilar medicines to different fora including but not limited to pharmacy and therapeutics committees, national and international advisory boards as well as patient organisations.

⁹ Personal communication with Pekka Kurki 20.04.17.

¹⁰ European Medicines Agency and the European Commission (2017), 2017. Biosimilars in the EU –Information guide for healthcare professionals. Available at: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (last visited on 10 June 2023).

¹¹ *Ibid.*

¹² *Ibid.* The terms and concepts mentioned are addressed more in detail by the Information guide for healthcare professionals.